La bourse est fermée
  • CAC 40

    5 609,15
    +34,79 (+0,62 %)
     
  • Euro Stoxx 50

    3 539,27
    +22,17 (+0,63 %)
     
  • Dow Jones

    30 218,26
    +248,74 (+0,83 %)
     
  • EUR/USD

    1,2127
    -0,0022 (-0,18 %)
     
  • Gold future

    1 842,00
    +0,90 (+0,05 %)
     
  • BTC-EUR

    15 713,81
    -1,96 (-0,01 %)
     
  • CMC Crypto 200

    365,19
    -14,05 (-3,71 %)
     
  • Pétrole WTI

    46,09
    +0,45 (+0,99 %)
     
  • DAX

    13 298,96
    +46,10 (+0,35 %)
     
  • FTSE 100

    6 550,23
    +59,96 (+0,92 %)
     
  • Nasdaq

    12 464,23
    +87,05 (+0,70 %)
     
  • S&P 500

    3 699,12
    +32,40 (+0,88 %)
     
  • Nikkei 225

    26 751,24
    -58,13 (-0,22 %)
     
  • HANG SENG

    26 835,92
    +107,42 (+0,40 %)
     
  • GBP/USD

    1,3438
    -0,0015 (-0,11 %)
     

Innate Pharma to Participate in upcoming investor conferences

INNATE PHARMA
·4 min de lecture

MARSEILLE, France, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.

  • Bryan Garnier & Co Virtual European Healthcare Conference
    Date: November 17, 2020
    Fireside Chat: November 17, 2020 at 10:00 a.m. CET

  • Jefferies Virtual London Healthcare Conference
    Date: November 18, 2020

  • SVB Leerink Oncology 1x1 Day
    Date: November 19, 2020

  • Oddo - Tech40 Digital Forum 5th Edition
    Date: November 24-25, 2020

  • Evercore ISI 3rd Annual HealthCONx
    Date: December 1-3, 2020
    Fireside Chat: December 2, 2020 at 8:50-9:10 a.m. ET

A replay of Innate’s presentation at the Bryan Garnier conference and a live webcast of Innate’s presentation at the Evercore ISI conference will be accessible through the News & Events page of the Investors section of the Company’s website at www.innate-pharma.com.

About Innate Pharma:
Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code
Ticker code
LEI

FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

Innate Pharma
Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com





Media

Innate Pharma
Tracy Rossin (Global/US)
Tel.: +1 240 801 0076
Tracy.Rossin@innate-pharma.com

ATCG Press
Marie Puvieux (France)
Tel.: +33 (0)9 81 87 46 72
innate-pharma@atcg-partners.com